دورية أكاديمية
Serum and cytosolic levels of CA549 in breast cancer patients.
| العنوان: | Serum and cytosolic levels of CA549 in breast cancer patients. |
|---|---|
| المؤلفون: | Correale M; RIA Laboratory, Oncology Institute of Bari, Italy., Abbate I, Dragone CD, Tedone T, Gargano G, Catino A, Paradiso A, Addabbo L, Musci MD, De Lena M |
| المصدر: | Clinical and experimental obstetrics & gynecology [Clin Exp Obstet Gynecol] 1993; Vol. 20 (4), pp. 264-7. |
| نوع المنشور: | Comparative Study; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: IMR Press Country of Publication: Singapore NLM ID: 7802110 Publication Model: Print Cited Medium: Print ISSN: 0390-6663 (Print) Linking ISSN: 03906663 NLM ISO Abbreviation: Clin Exp Obstet Gynecol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2021- : Singapore : IMR Press Original Publication: Padova : S.O.G |
| مواضيع طبية MeSH: | Antigens, Tumor-Associated, Carbohydrate/*biosynthesis , Biomarkers, Tumor/*biosynthesis , Breast Neoplasms/*immunology , Cytosol/*immunology , Glycoproteins/*biosynthesis, Antibodies, Monoclonal ; Antigens, Tumor-Associated, Carbohydrate/blood ; Biomarkers, Tumor/blood ; Breast Neoplasms/blood ; Female ; Glycoproteins/blood ; Humans ; Immunoenzyme Techniques ; Immunoradiometric Assay ; Sensitivity and Specificity |
| مستخلص: | CA 549 is a new mucinous circulating tumor marker recognized by two monoclonal antibodies (BC4E549 and BC4N154) recently proposed for breast cancer. In this report we compared the levels of CA 549 and CA 15.3, the best known biomarker for breast cancer nowadays, in 68 sieric and 59 cytosolic samples. Serum samples came from 59 breast patients (24 with primary disease = M-, 18 with systemic disease = M+, 17 with no evidence of disease after surgery = NED) and 9 women with benign breast disease = BBD. The cytosols were prepared from primary breast carcinomas according to the method used for hormonal receptors. At first we evaluated the analytical performance of the immunoradiometric assay for CA 549 (Hybri-BREScan, Hybritech) and its applicability to the cytosolic determination. Using a cut-off value of 12 U/mL for CA 549 and 28 U/mL for CA 15.3 serum levels, we obtained the following percentages of positivities: M- = 21%; M+ = 83%; NED = 0%; BBD = 22% for CA 549 and M- = 33%; M+ = 89%; NED = 18%; BBD = 22% for CA 15.3. CA 549 gave information concordant with CA 15.3 in a high percentage of cases both in sera and in cytosols, but the clinical relevance of cytosolic determination remains to be investigated. Since serum CA 549 showed an adequate sensitivity in M+ patients only, it may be proposed in the follow-up to confirm CA 15.3 abnormal values or as an alternative to it. |
| المشرفين على المادة: | 0 (Antibodies, Monoclonal) 0 (Antigens, Tumor-Associated, Carbohydrate) 0 (Biomarkers, Tumor) 0 (CA549 glycoprotein, human) 0 (Glycoproteins) |
| تواريخ الأحداث: | Date Created: 19930101 Date Completed: 19940214 Latest Revision: 20200923 |
| رمز التحديث: | 20221213 |
| PMID: | 8281711 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 0390-6663 |
|---|